new indications for glp-1 drugs Orforglipron, approved as Foundayo on April 1, 2026, adds another oral option chronic weight management in adults with obesity or overweight plus at least one weight-related condition. The clinical relevance Many people remain excluded from
Pay in 4 interest-free payments of $6.64 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28



























